•  
  •  
 

Corresponding Author

Abd Elmonaem, Abd Elmonaem

Document Type

Original Article

Abstract

Background: Worldwide, lung cancer representing 13% of all new cancer cases And has the highest mortality rate . In Egypt, lung cancer incidence is about 4.6% of all cancers . recent trials reporting that immune therapy (anti PDL1) showed a significant superior progression-free survival (PFS) and overall survival (OS) if compared with standard chemotherapy Objectives: To assess outcome of treatment in patients with metastatic non-small cell lung cancer at presentation, in term of response to treatment, progression free survival and, overall survival, treatment related toxicity. Patients and Methods: patient related data: Age, sex, special habits, and performance status. Disease related data: date of diagnosis, extent of disease, histopathology details and sites of metastasis , Treatment related data:- Chemotherapy (regimen ,cycles , response related toxicity ), Radiotherapy (site , related toxicity ) ,Response to treatment according to RECIST criteria .Progression free survival, Overall survival . Results: our study among 56 patients, 29 patients received chemotherapy. radiotherapy used for palliation of symptoms , patients who received chemotherapy showed improvement of progression free survival and overall survival when compared with those who didn’t receive chemotherapy, there were no available data about quality of life , because of unavailability of resources we didn’t use targeted or immune therapies Conclusion: patients with metastatic NSCLC, if molecular tests of gene mutations and checkpoints expressions not available , a four to six cycles of platinum based chemotherapy is indicated in patients with good performance status as regard that chemotherapy showed survival benefit versus best supportive care

Keywords

Metastatic; lung; Cancer

Download

Share

COinS